Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Upstream Bio, Inc.NASDAQ: UPB
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 1184.0% from a year ago
Other current liabilities stood at $11.24M at the end of Q1 FY2026, up 1184.0% from a year earlier and up 12.3% from the prior quarter. Over 3 fiscal years it compounded at +123.8% a year.
Context
- Other current liabilities amounted to 3.5% of total assets at the end of Q1 FY2026, up 3.3 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +1184.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.01M USD
- Year-over-year change
- +271.0%
- 3-year CAGR
- +123.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.01M | +271.0% |
| FY2024 | 2024-12-31 | 2.7M | +24.4% |
| FY2023 | 2023-12-31 | 2.17M | +142.8% |
| FY2022 | 2022-12-31 | 893K | — |
Other Current Liabilities vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1184.0% is the 2nd highest of 10, against a peer median of +23.8%.
- Other current liabilities amounts to 3.5% of total assets for UPB, versus a peer median of 3.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $132.45M USD | -6.7% | -37.8% | 12.7% | |
| Mar 2026 | $45.44M USD | +1243.3% | +111.9% | 6.1% | |
| Sep 2026 | $40.14M USD | +145.9% | +84.6% | 3.7% | |
| Mar 2026 | $18.2M USD | -30.4% | +150.6% | 3.9% | |
UPBUpstream Bio, Inc. | Mar 2026 | $11.24M USD | +1184.0% | +123.8% | 3.5% |
| Sep 2026 | €10.19M EUR | +28.5% | +191.6% | 3.5% | |
| Mar 2026 | $9.32M USD | -5.3% | +1.9% | 1.2% | |
| Mar 2026 | $5.52M USD | +23.8% | +13.7% | 0.9% | |
| Jun 2026 | $1.25M USD | +105.6% | -73.9% | 0.1% | |
| Sep 2026 | $0 USD | -100.0% | -12.9% | 0.0% | |
| Peer median (excluding UPB) | — | +23.8% | +13.7% | 3.5% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.